Zealand Pharma A/s

Antag Therapeutics Aps

Other

Boehringer Ingelheim International Gmbh

Ditte Riber

Jakob Lind Tolborg

Dieter Wolfgang Hamprecht

Eddi Meier

Rasmus Just

Jens Rosengren Daugaard

Wolfgang Rist

Marie Skovgaard

Leo Thomas

Bjarne Due Larsen

Torben Østerlund

Anne Pernille Tofteng Shelton

Pia Nørregaard

Keld Fosgerau

Robert Augustin

Kirsten Lindegaard Bovbjerg

Wayne Shaun Russell

Lene Jessen

Kate Hansen

Lise Giehm

Trine Skovlund Ryge Neerup

Mette Marie Rosenkilde

Camilla Ærteberg Bæk

Gita Kampen

Bjørn Behrens Sivertsen

Alexander Hovard Sparre-ulrich

Torben Osterlund

Simon Birksø Larsen

Trine Skovlund Ryge

Pia Norregard

Camilla ÆRteberg BÆK

Lene Axelsen

Jørgen Søberg Petersen

Torben ØSterlund

Pia NØRREGARD

Anne Pernille Shelton

Rie Schultz Hansen

Henrik Duelund Pedersen

Anne Louise Kjoelbye

Disclosed are glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues which are antagonists of the GIP receptor. These GIP peptide analogues are modified by comprising one or more individual amino acid substitutions and are fatty acid conjugated with/without a linker, so to have improved antagonistic activity and improved pharmacokinetic profile.

Modified GIP peptide analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Acylated glucagon analogues

The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

Glucagon analogues

Acylated glucagon analogue

The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

Glucagon-GLP-1-GIP triple agonist compounds

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Glucagon analogues and methods of use

The present invention relates to glucagon analogs and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogs suitable for use in a liquid formulation.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.

Glucagon-like-peptide-2 (GLP-2) analogues

The present invention relates to truncated GIP analogs which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.

GIP-GLP-1 dual agonist compounds and methods

Growing community of inventors

Brønshøj, Denmark

Ditte Riber